Lixte Biotechnology Holdings Inc (LIXT) - Total Assets
Based on the latest financial reports, Lixte Biotechnology Holdings Inc (LIXT) holds total assets worth $12.73 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Lixte Biotechnology Holdings Inc balance sheet quality to measure how much of total assets are equity-financed.
Lixte Biotechnology Holdings Inc - Total Assets Trend (2005–2025)
This chart illustrates how Lixte Biotechnology Holdings Inc's total assets have evolved over time, based on quarterly financial data. Check LIXT cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Lixte Biotechnology Holdings Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Lixte Biotechnology Holdings Inc's total assets of $12.73 Million consist of 40.7% current assets and 59.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Lixte Biotechnology Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Lixte Biotechnology Holdings Inc (LIXT) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lixte Biotechnology Holdings Inc's current assets represent 40.7% of total assets in 2025, a decrease from 100.0% in 2005.
- Cash Position: Cash and equivalents constituted 40.1% of total assets in 2025, down from 100.0% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Lixte Biotechnology Holdings Inc Competitors by Total Assets
Key competitors of Lixte Biotechnology Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Lixte Biotechnology Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.88 | 3.60 | 32.55 |
| Quick Ratio | 3.88 | 3.60 | 32.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.85 Million | $827.22K | $7.65 Million |
Lixte Biotechnology Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Lixte Biotechnology Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.56 |
| Latest Market Cap to Assets Ratio | 4.71 |
| Asset Growth Rate (YoY) | 1011.6% |
| Total Assets | $12.73 Million |
| Market Capitalization | $59.95 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Lixte Biotechnology Holdings Inc's assets at a significant premium (4.71x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Lixte Biotechnology Holdings Inc's assets grew by 1011.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Lixte Biotechnology Holdings Inc (2005–2025)
The table below shows the annual total assets of Lixte Biotechnology Holdings Inc from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $12.73 Million | +1011.62% |
| 2024-12-31 | $1.15 Million | -73.41% |
| 2023-12-31 | $4.31 Million | -22.51% |
| 2022-12-31 | $5.56 Million | +9.16% |
| 2021-12-31 | $5.09 Million | -2.59% |
| 2020-12-31 | $5.23 Million | +95.67% |
| 2019-12-31 | $2.67 Million | -38.39% |
| 2018-12-31 | $4.34 Million | +217.00% |
| 2017-12-31 | $1.37 Million | +215.65% |
| 2016-12-31 | $433.41K | -27.52% |
| 2015-12-31 | $597.98K | +10.88% |
| 2014-12-31 | $539.30K | -3.36% |
| 2013-12-31 | $558.04K | -68.17% |
| 2012-12-31 | $1.75 Million | +307.90% |
| 2011-12-31 | $429.77K | -77.75% |
| 2010-12-31 | $1.93 Million | +20.61% |
| 2009-12-31 | $1.60 Million | +3000.20% |
| 2008-12-31 | $51.65K | -91.79% |
| 2007-12-31 | $629.11K | -16.24% |
| 2006-12-31 | $751.07K | +16118.25% |
| 2005-12-31 | $4.63K | -- |
About Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-… Read more